1. In Vivo
  2. >>Innovation

Treat, Prevent, Restore: Sensorion’s Approach To Hearing Loss

French Biotech Is Developing Small Molecules And Gene Therapies

 
• By Chloe Kent

Hearing loss lacks pharmacological treatment options, with patients instead relying on medical devices or going untreated. In Vivo spoke to French biotech Sensorion, which is targeting a number of hearing loss indications with small-molecule drugs and gene therapies.

Adult woman and young girl conversing in sign language at a playground
• Source: Shutterstock

A lack of approved pharmacological therapies for hearing loss, whether acquired or congenital, is a gap in the market that a number of biotechs and big pharmaceutical firms are looking to plug. While medical devices such as hearing aids or cochlear implants can be a boon for patients who are deaf or hard of hearing, a lack of drug treatment options represents a significant unmet medical need.

“The biological approaches a patient needs are very different” depending on whether their hearing loss can be treated or prevented,...

More from Innovation

In Conversation With Foundation Fighting Blindness

 
• By David Wild

Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy